2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Targeted Alpha-emitter Therapy of Neuroendocrine Tumors Using Pb212-octerotate

Ottawa, ON, Canada (UroToday.com) Nine patients with no previous history of radiotherapy with Lu177 or Y90 were enrolled in a study of the efficacy of Pb212-octreotate in the treatment of neuroendocrine tumors. Dose escalation studies were conducted on 3 cohorts of 3 patients each with 30% incremental doses between each cohort. Tumor size an function were monitored with MRI and F18-FDG PET scans. The treatments were well tolerated with only a few mild side effects reported. Efficacy studies are ongoing.


Presented by: Dr. Ebrahim S. Delpassand, MD, founder and current Chief Executive Officer of RadioMedix, Inc

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada